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Abstract
Background: NEDD1 is a protein that binds to the gamma-tubulin ring complex, a multiprotein
complex at the centrosome and at the mitotic spindle that mediates the nucleation of microtubules.
Results: We show that NEDD1 is expressed at comparable levels in a variety of tumor-derived
cell lines and untransformed cells. We demonstrate that silencing of NEDD1 expression by
treatment with siRNA has differential effects on cells, depending on their status of p53 expression:
p53-positive cells arrest in G1, whereas p53-negative cells arrest in mitosis with predominantly
aberrant monopolar spindles. However, both p53-positive and -negative cells arrest in mitosis if
treated with low doses of siRNA against NEDD1 combined with low doses of the inhibitor BI2536
against the mitotic kinase Plk1. Simultaneous reduction of NEDD1 levels and inhibition of Plk1 act
in a synergistic manner, by potentiating the anti-mitotic activity of each treatment.
Conclusion: We propose that NEDD1 may be a promising target for controlling cell proliferation,
in particular if targeted in combination with Plk1 inhibitors.
Background
The centrosome is a cellular structure responsible for the
nucleation and organisation of microtubules. Because the
centrosome is duplicated prior to cell division, during S-
phase, the resulting two organising centres ensure the
assembly of a bipolar spindle in mitosis, allowing the cor-
rect segregation of chromosomes. Considerable interest
has focused on the role of the centrosome in cancer,
because frequent abnormalities are found in tumor cells,
such as supernumerary centrosomes or increased expres-
sion of centrosome proteins [1,2]. This phenomenon is
also termed "centrosome amplification", and has often
been correlated with aggressive tumor growth. Although it
has not been formally demonstrated that centrosome
amplification can cause cancer, centrosome abnormalities
can generate defective mitotic spindles and therefore lead
to mis-segregation of chromosomes and to aneuploidy
[1,3]. However, in most cases spindle defects arrest the cell
cycle in mitosis by activating the spindle assembly check-
point, and lead to cell death.
Experiments in recent years suggested that the centrosome
might also play a role at the transition from G1 into S-
phase in the cell cycle. [4] and [5] showed that removing
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the centrosome from untransformed cultured cells by
microsurgery or by laser ablation arrests the cell cycle in
G1 phase. Further experiments by different research
groups indicated that inhibition or silencing of individual
centrosome components also impedes cell cycle progress
into S-phase [6-11]. Molecular analysis revealed that this
is due to activation of the stress signalling pathway, by
activating the kinase p38 and the p53-dependent G1/S
checkpoint control system [10-12].
We think that centrosome proteins may represent new
original targets for anticancer therapy. Consistent with
this idea, inhibiting the expression of several centrosome
proteins has recently been found to sensitize lung cancer
cells to the chemotherapeutic agent paclitaxel: in a syn-
thetic lethal screen to identify genes that reduce cell viabil-
ity when silenced by siRNA in the presence of sublethal
concentrations of paclitaxel, several proteins of the
gamma-tubulin ring complex were identified among the
top targets [13]. The list of these proteins comprises
gamma-tubulin, GCP2, GCP3, GCP5, and NEDD1.
GCP2, 3, and 5 belong to a family of related proteins con-
taining so-called 'grip' motifs (gamma-tubulin ring com-
plex motifs), and together with GCP4, GCP6, and
gamma-tubulin, they form the core of the gamma-tubulin
ring complex (gamma-TuRC). NEDD1 has been proposed
to associate peripherally with the gamma-TuRC, and to
act as a recruitment factor to anchor gamma-TuRCs to the
centrosome [14,15]. The function of the gamma-TuRC at
the centrosome is to nucleate microtubules, supporting
the assembly of the mitotic spindle. Depletion of NEDD1
inhibits gamma-TuRC recruitment to the centrosome,
preventing centrosomal microtubule nucleation and the
formation of a functional spindle [14,15]. Depleted HeLa
cells are blocked in mitosis due to activation of the spin-
dle assembly checkpoint [14]. Combined with the find-
ings by [13], these results suggest that NEDD1 may
represent an interesting, novel anti-cancer target. To deter-
mine whether NEDD1 constitutes a potential target for
future anti-cancer therapy, we investigate here the conse-
quences of NEDD1-depletion by RNA silencing in a vari-
ety of cancer cell lines, and we analyse the effects of
depletion on the cell cycle and on potential sensitisation
to anti-mitotic agents.
Results
To assess the importance of NEDD1 for cancer cell
growth, we tested a variety of cell lines for NEDD1 expres-
sion by immunoblotting. These included HeLa (cervix car-
cinoma), DU145 (prostate carcinoma), DLD-1 (colon
carcinoma), SKOV-3 (ovarian adenocarcinoma), MDA-
MB-231 (breast carcinoma), BxPc-3 (pancreas adenocarci-
noma), and A549 (lung carcinoma). NEDD1 levels were
normalised using actin as a loading control, and HeLa
cells were used as a reference because these cells have been
previously used for the characterization of the protein
[14,15]. Figure 1A shows that the amounts of NEDD1 do
not vary much between the cell lines. Moreover, similar
amounts were detected in two different cell lines derived
from colon carcinoma (HCT116 p53+/+ and -/-), and in
non-cancerous cells such as MRC-5 fibroblasts and fore-
skin fibroblasts (Figure 1A), indicating that NEDD1
expression is not strongly deregulated in cancer cells.
In a second step, we examined the consequences of
NEDD1-depletion on the cell cycle by flow cytometry. To
lower the protein levels of NEDD1, we performed RNA
silencing for 72 hours with previously characterized
siRNA oligomers [14]. Because of different transfectability
and different response to siRNA treatment, the efficiency
of NEDD1-depletion varied between the different cell
lines. As shown in Figure 1B, cell cultures of HeLa,
DU145, DLD-1, SKOV-3, and A549 were efficiently
depleted (removal of more than 70% of NEDD1). In
MDA-MB-231 and BxPc-3 cells, RNA silencing was less
efficient and cell cycle analysis not done. Reduced NEDD1
expression led to a significant accumulation of HeLa cells
in G2/M phase (increase from 12% to 50%), consistent
with the accumulation in mitosis described in previously
published work [14]. An increase in G2/M levels was also
noticeable, although less dramatically (but reproducibly),
in DLD1, DU145 and SKOV-3 cells (Figure 1B). These
cells display a higher doubling time than HeLa, which
could explain why they did not efficiently accumulate in
mitosis. Indeed, treatment of DU145 cells for 96 h signif-
icantly increased the relative amount of G2/M phase
(51%; data not shown).
Interestingly, A549 cells showed a decrease of the percent-
age in G2/M phase (from 26% to 16%). A549 cells express
wild-type p53 protein, in contrast to HeLa, DLD1,
DU145, and SKOV-3, in which the p53-dependent check-
point control is compromised due to regulatory defects or
mutations in p53. We therefore reasoned that different
flow cytometry profiles might be due to differences in
checkpoint control in the various cell lines. The observed
decrease of A549 cells in G2/M phase was accompanied
by an increase of the G1/S population. This is consistent
with other data indicating that the G1/S transition is
inhibited if centrosome integrity is disturbed in p53 wild-
type cells [10-12]. To investigate this problem in more
detail, we focused on the isogenic cell lines HCT116 p53
+/+ and p53 -/- (Figure 2A, Figure 2B, Figure 2C) that dif-
fer only in the expression of the p53 gene [16]. Depletion
of more than 80% of NEDD1 was achieved by RNA silenc-
ing for 48 hours in both cell lines (Figure 2A). Flow
cytometry clearly showed that only p53-negative cells
accumulated in G2/M phase upon NEDD1-depletion
(increase from 22% to 48%, Figure 2B). Consistently, the
percentage of p53-negative cells with cyclin B1 stainingMolecular Cancer 2009, 8:10 http://www.molecular-cancer.com/content/8/1/10
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NEDD1 expression levels in cancer cell lines and effect of depletion on the cell cycle Figure 1
NEDD1 expression levels in cancer cell lines and effect of depletion on the cell cycle. (A) NEDD1 expression levels 
were analysed by immunoblotting using anti-NEDD1 antibody. Anti-actin antibody was used as a control. Bottom: ratio of the 
signals of NEDD1/actin, obtained by quantitative immunoblotting from five independent experiments (error bars represent 
SD). (B) Flow-cytometric analysis of cell lines treated with control siRNA or siRNA targeting NEDD1 at 50 nM for 72 h, and 
labelled with propidium iodide. Depletion levels of NEDD1 are shown for each cell line. Immunoblots were probed with anti-
NEDD1 and anti-actin antibodies.
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nearly doubled (from 22% to 39%), indicating that cells
accumulate in mitosis, whereas the percentage of p53-
positive cells in mitosis remained approximately constant
(Figure 3A, Figure 3B). To further resolve how p53-nega-
tive cells accumulate in mitosis, we performed immun-
ofluorescence analysis of HCT116 cells by staining for
microtubules. Counting of mitotic figures revealed a five-
fold increase of the mitotic index in p53-negative cells,
accumulating at approximately 22% in mitosis with
monopolar spindles, whereas p53-positive cells didn't
show any significant increase of mitotic stages (Figure 3C,
Figure 3D). Consistently, p53-negative cells showed an
Depletion of NEDD1 reduces cell proliferation of HCT116 p53+/+ and HCT116 p53 -/- cells Figure 2
Depletion of NEDD1 reduces cell proliferation of HCT116 p53+/+ and HCT116 p53 -/- cells. (A) Immunoblots of 
HCT116 p53+/+ and HCT116 p53 -/- cells treated with control siRNA or siRNA targeting NEDD1, at 50 nM for 72 h. Blots 
were probed with antibodies against NEDD1 and actin. (B) Flow-cytometric analysis of HCT116 p53+/+ and HCT116 p53 -/- 
cells treated with control RNA or NEDD1-siRNA for 48 h, and labelled with propidium iodide (C) Number of living cells quan-
tified by trypan blue exclusion analysis, 48 h after transfection of control RNA or NEDD1-siRNA, at 25 nM (error bars repre-
sent SD from three independent experiments).
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Mitotic arrest after NEDD1-depletion depends on the checkpoint protein p53 in HCT116 cells Figure 3
Mitotic arrest after NEDD1-depletion depends on the checkpoint protein p53 in HCT116 cells. (A) Flow-cyto-
metric analysis of HCT116 p53+/+ and HCT116 p53 -/- cells treated with control RNA or siRNA targeting NEDD1 at 50 nM 
for 72 h and double-labelled with propidium iodide and FITC-conjugated anti-cyclinB1 antibody. (B) Quantification of cyclinB1-
positive cells (error bars represent SD from three independent experiments). (C) Immunofluorescence of mitotic HCT116 
p53+/+ and p53 -/- cells, 72 h after transfection with control or NEDD1-siRNA, using anti-alpha tubulin and DAPI staining. Bar, 
20 μm. (D) Percentage of mitotic cells shown in (C). 500 cells were scored per condition (error bars represent SD from three 
independent experiments). (E) Immunoblots of HCT116 p53+/+ and p53 -/- cells treated 48 h with control or NEDD1-siRNA. 
Blots were probed with antibodies against phospho-histone H3 and actin.
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increase of phosphorylated histone H3 by immunoblot-
ting, indicative of mitotic accumulation (Figure 3E).
To examine the fate of p53-positive cells, we performed
labelling experiments with bromodeoxyuridine (BrdU),
which is incorporated into newly synthesized DNA in
cells during S-phase (Figure 4). Our experiments show
that p53-positive HCT116 cell cultures incorporate less
than half of the regular BrdU amounts, indicating that
cells are blocked or delayed prior to S-phase (Figure 4A,
Figure 4B). Equivalent results were obtained with the
A549 cells (Figure 4C, Figure 4D). Thus we show that cells
respond differently to NEDD1-depletion dependent on
their p53 status: in the absence of functional p53 cells
arrest in mitosis, but in cells expressing wild type p53 the
cycle already stops in G1/S. Despite these differences, sup-
pression of NEDD1 reduced the proliferation of both p53-
positive and negative HCT116 cells equally, by approxi-
mately 40% after 48 h siRNA treatment (Figure 2C).
Because depletion of proteins of the gamma-tubulin com-
plex sensitizes p53-mutated cells derived from non-small
cell lung cancer for the treatment with the chemothera-
peutic agent paclitaxel [13], we wanted to confirm that
specific depletion of NEDD1 had a similar effect in HeLa
and in HCT116 cells with and without p53 (Figure 5A,
Figure 5B, Figure 5C, Figure 5D, Figure 5E, Figure 5F, Fig-
ure 5G). The previously published screen for chemosensi-
tizers by [13] was performed at high concentrations of
siRNA for 48 h, followed by 48 h treatment with paclit-
axel. When we applied high doses of siRNA against
NEDD1 in our own experiments for 48 h, we already
noticed a high cytotoxicity before paclitaxel addition (Fig-
ure 2C and data not shown). We thus lowered the concen-
tration of siRNA and added paclitaxel 4 hours after the
start of the transfection, for a total of 48 h of transfection.
Cells were treated with a range of low concentrations of
siRNA (0–2.5 nM) and of paclitaxel (0–5 nM). However,
under these conditions, no significant sensitising effect
was observed when both treatments were combined (Fig-
ure 5D, Figure 5F, and data not shown). In Figure 5D,
HeLa cells were treated with 0.5 nM NEDD1-siRNA and
2.5 nM paclitaxel. Alone, these treatments yielded approx-
imately 80% of viable cells compared to cells treated with
control siRNA. Simultaneous application of both paclit-
axel and NEDD1-siRNA did not reduce further the
number of viable cells. The same results were found at var-
iable doses of paclitaxel (Figure 5F). Subsequently, we
tested other anti-mitotic agents: BI2536 is a potent and
specific inhibitor of the mitotic kinase Plk1 and inhibits
tumor growth in vivo [17]. Both, the inhibition of Plk1
and the depletion of NEDD1 produce similar phenotypes:
inhibition of gamma-TuRC recruitment to the centro-
some and inhibition of centrosomal microtubule nuclea-
tion, yielding monopolar spindles in mitosis [14,15,18-
20]. We therefore tested whether siRNA targeting NEDD1
would sensitise cells to the Plk1 inhibitor. HeLa and
HCT116 cells (p53 +/+ and -/-) were treated with 0.5 nM
siRNA and 5 nM (HeLa) or 10 nM (HCT116) BI2536 for
48 h (Figure 5A). In all three cell lines, combined treat-
ment reduced the number of viable cells further than any
independent treatment: in HCT116 p53-/- cells, com-
bined treatment yielded 34% of viable cells compared to
cells treated with control siRNA, whereas single NEDD1-
siRNA or drug treatment yielded 67% or 74% of viable
cells respectively. In HCT116 p53+/+ cells, 50% of viable
cells were counted after combined treatment, compared to
77% after siRNA or 85% after drug treatment alone. In
HeLa cells, 33% of viable cells were counted after com-
bined treatment, compared to 77% or 66% after single
siRNA or drug treatment, respectively. Calculation of the
combination index (CI), based on the dose response
curves of single NEDD1-siRNA and BI2536 treatment
(Figure 5B, Figure 5C, and data not shown) led to a value
of CI < 0.3, indicating a strong synergy [21]. For compari-
son, combination of NEDD1-siRNA and taxol led to a
value of CI > 1 which indicates antagonism. A more
detailed analysis was performed in HeLa cells, treated
with a range of low concentrations of siRNA. The graph in
Figure 5B shows dose response curves after treatment with
NEDD1-siRNA, alone or in combination with the Plk1
inhibitor, as well as a theoretical additive effect, calculated
according to [22] (see 'Methods' for details). The graph
illustrates that synergy occurs even at the lowest concen-
trations of NEDD1-siRNA. Inversely, treatment with
NEDD1-siRNA also increased the anti-proliferative effect
of BI2536 at a range of concentrations below 5 nM of this
drug (Figure 5C).
Finally, we tested a possible synergy with monastrol, a
specific inhibitor of Eg5, which also blocks cells in mitosis
by inducing monopolar spindles [23]. HeLa cells were
treated as described for paclitaxel and BI2536. Figure 5E
shows an enhancement of the anti-proliferative effect fol-
lowing combined treatment with 0.5 nM NEDD1-siRNA
and 60 μM monastrol, yielding 58% of viable cells com-
pared to 79% or 76% after single siRNA or drug treatment,
respectively. However, in this case calculation of the com-
bination index indicated an additive effect (CI = 1), but
no synergy. This effect was also seen at higher doses of the
drug (Figure 5G).
To better understand the mechanism of the synergy
between siRNA against NEDD1 and Plk1 inhibition, we
analysed the cell cycle profiles by flow cytometry follow-
ing treatments.
Treatment of HCT116 cells with either NEDD1-siRNA or
BI2536 alone showed little effect on the cell cycle com-
pared to control siRNA treatment (Figure 6). Only a subtleMolecular Cancer 2009, 8:10 http://www.molecular-cancer.com/content/8/1/10
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Depletion of NEDD1 prevents DNA replication and leads to cell cycle arrest in G1 or G0 phase in HCT116 p53+/+ and A549  (p53WT) cell lines Figure 4
Depletion of NEDD1 prevents DNA replication and leads to cell cycle arrest in G1 or G0 phase in HCT116 
p53+/+ and A549 (p53WT) cell lines. HCT116 p53+/+ (A) or A549 (B) cells were treated with control siRNA or siRNA 
targeting NEDD1 at 50 nM for 48 h, then inbubated with BrdU for 90 minutes. Left: Flow-cytometric analysis of cells labelled 
with 7-AAD and FITC-conjugated anti-BrdU antibody. Right: Quantification of BrdU incorporation in control or NEDD1-
siRNA-treated cells. 20,000 cells were scored per condition (error bars represent SD from three independent experiments).
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increase in the G2/M population was seen, whereas simul-
taneous treatment led to a strong enhancement of the G2/
M peak (Figure 6A). Remarkably, this was found in both
p53 +/+ and -/- cells. Similar results were found in HeLa
cells (Figure 6B). Moreover, analysis of the mitotic figures
by immunofluorescence revealed that the increase of the
G2/M population correlated with larger amounts of
monopolar spindles (Figure 6B). Thus combination of
both treatments enhances their anti-mitotic effect due to
an enhanced inhibition of bipolar spindle formation.
Discussion
Cells in mitosis represent a validated target in anti-cancer
therapy. Strategies that are currently used, such as treat-
ment with microtubule inhibitors, e.g. taxans or vinca
alkaloids, arrest cycling cells in mitosis by interfering with
microtubule dynamics. Because of secondary effects in
normal cells and also because of resistance of cancer cells
to such treatments, new targets have been explored, lead-
ing to the development of inhibitors of mitotic kinases
such as Plk1 or Aurora, or of motor proteins such as Eg5
[24]. These proteins control the transformation of the
microtubule network into a functional bipolar spindle.
Inhibition of these factors induces abnormal spindles, fol-
lowed by mitotic arrest due to activation of the spindle
assembly checkpoint, resulting in frequent cell death.
Likewise, the centrosome protein NEDD1 is essential for
spindle assembly. More specifically, NEDD1 is needed for
the sudden increase of gamma-TuRC-binding to the cen-
trosome at the onset of mitosis, and for the resulting
increase of microtubule nucleation [14,15,25]. We have
previously shown that depletion of NEDD1 from HeLa
cells induces accumulation of cells in mitosis with
monopolar spindles [14]. We show here that NEDD1
The Plk1 inhibitor BI2536 and siRNA against NEDD1 act synergistically to reduce cell viability Figure 5
The Plk1 inhibitor BI2536 and siRNA against NEDD1 act synergistically to reduce cell viability. (A) Quantification 
of HCT116 p53+/+, p53-/-, or HeLa cells surviving after control RNA or NEDD1-siRNA transfection (0.5 nM) alone, or com-
bined with BI2536 (10 nM in HCT116 cells, 5 nM in HeLa cells). The percentage of surviving cells is indicated as a percentage of 
the number of control cells (treated with control siRNA, without BI2536), quantified by trypan blue exclusion analysis after 48 
h incubation. (B) Percentage of viable HeLa cells after 48 h treatment with variable concentrations of NEDD1-siRNA alone, or 
combined with 5 nM BI2536. (C) Percentage of viable HeLa cells after 48 h treatment with variable concentrations of BI2536 
combined with 0.5 nM control or NEDD1-siRNA. (D, E) Percentage of viable HeLa cells after 48 h treatment with control or 
NEDD1-siRNA (0.5 nM) alone, or combined with paclitaxel (2.5 nM, D) or monastrol (60 μM, E). (F, G) Percentage of viable 
HeLa cells after 48 h treatment with variable concentrations of paclitaxel (F) or monastrol (G) combined with 0.5 nM control 
or NEDD1-siRNA. Error bars represent SD from six (A) or three (B-G) independent experiments. In B, C, F, G, dose-
response curves for theoretical additive effects, calculated according to [22], are included for comparison (dotted line).
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Depletion of NEDD1 potentiates the anti-mitotic activity of the Plk1 inhibitor BI2536 Figure 6
Depletion of NEDD1 potentiates the anti-mitotic activity of the Plk1 inhibitor BI2536. (A) Flow-cytometric analy-
sis of HCT116 p53+/+ and p53-/- cell lines treated for 48 h with control or NEDD1-siRNA (0.5 nM) alone or combined with 
BI2536 (10 nM) and labelled with propidium iodide. (B) Quantification of G2/M HeLa cells following flow-cytometric analysis, 
after treatment for 48 h with control or NEDD1-siRNA (0.5 nM) alone, or combined with BI2536 (5 nM). (C) Quantification of 
monopolar spindles (as a percentage of total prometa-metaphase spindles) present in HeLa cells treated for 48 h with control 
or NEDD1-siRNA (0.5 nM) alone, or combined with BI2536 (5 nM).
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expression is not deregulated in cancer cells: NEDD1 is
expressed at comparable levels in a variety of cancer cell
lines and in normal cells. However, lowering its expres-
sion slows down cell proliferation and enhances the anti-
proliferative effect of Plk1 inhibition.
Treatment with siRNA against NEDD1 has different effects
on the cell cycle depending on the p53 status of the cell
lines: accumulation of cells in G1 is observed if the p53-
dependent G1/S checkpoint is functional, consistent with
published data indicating that centrosome abnormalities
can trigger the cellular stress response via p38 and cause
p53-dependent cell cycle arrest [10-12]. In cells without a
functional p53-dependent checkpoint, the cell cycle is
arrested during mitosis, due to the formation of monopo-
lar spindles. Moreover, we show that very low concentra-
tions of NEDD1-siRNA treatment potentiate the mitotic
inhibition induced by BI2536, a strong inhibitor of Plk1
[17,18]. Remarkably, this effect is independent of the p53
status of the cells. Under the conditions of our experi-
ment, using low concentrations of siRNA, the treatment
did not induce a significant G1/S arrest in HCT116 p53+/
+ cells, probably because the stress response was not trig-
gered [12]. Thus, cells passed the G1/S checkpoint and
arrested in mitosis due to the combined effect of the
reduction of NEDD1 levels and Plk1 inhibition.
We demonstrate that siRNA against NEDD1 and inhibi-
tion of Plk1 act synergistically to reduce cell numbers,
exceeding by far a simple additive effect of both treat-
ments. We show that the reduced viability after simultane-
ous treatment is associated with an increase of abnormal
mitotic spindle assembly. Individual treatments produce
similar spindle defects in mitosis: NEDD1 or Plk1-
dependent defects induce formation of monopolar spin-
dles which activate the spindle assembly checkpoint
[14,15,18-20,26-31]. We think that Plk1 and NEDD1 act
in a common pathway: they are both necessary for the
recruitment of the gamma-TuRC to the centrosome early
in mitosis [14,15,18,28,31]. This is a prerequisite for
amplification of microtubule assembly and for the separa-
tion of the spindle poles. Thus inhibition of both proteins
would amplify the loss of gamma-TuRC recruitment and
the formation of monopolar spindles, producing a syner-
gistic effect.
In contrast, monastrol also produces monopolar spindles
and activates the mitotic checkpoint, but only yields an
additive effect together with NEDD1 depletion. Likely,
this is because monastrol acts in a different, parallel path-
way of spindle assembly, by inhibiting the motor protein
Eg5 and disrupting the forces of antiparallel microtubule
sliding that is necessary to separate the two centrosomes
[23].
At low concentration of paclitaxel, we see neither a syner-
gistic, nor an additive effect on the proliferation of cells
when combined with siRNA against NEDD1. At first
glance, these results seem to contrast with the screening
data of [13]. However, our experiments were performed in
different cell lines, at lower concentration of siRNA
against NEDD1, and using different durations of treat-
ment. We think that the discrepancies might be explained
as follows: first, under the conditions of [13], cells are
depleted of NEDD1 with high doses of siRNA before pacl-
itaxel treatment, which should arrest them in mitosis
before application of the drug. In these mitotic cells, pacl-
itaxel may have an enhanced cytotoxicity as compared to
interphase cells. Second, it is known that sensitivity to
paclitaxel varies considerably between cancer cell lines,
with more than 20-fold variation of the apoptotic index
[32]. Combination treatment might thus yield different
results depending on the cell line.
Conclusion
Altogether, our data suggest that interfering with the func-
tion of NEDD1 slows down proliferation, in particular in
combination with other reagents that block mitosis, such
as Plk1 inhibitors. Suppression of NEDD1 induces defects
in centrosome function that arrest the cell cycle. Whether
NEDD1 is indeed a potential target for cancer therapy
remains to be determined in animal models in vivo. At
present, it is encouraging to note that even very low doses
of siRNA against NEDD1 affect cell growth in synergy with
Plk1 inhibition. Moreover, under these conditions we
observe no apparent abnormalities on interphase micro-
tubules (unpublished observation). Therefore, the combi-
nation of inhibitors against NEDD1 and other mitotic
targets should have the advantage for eventual therapeutic
use to produce minimal side effects in interphase cells and
should thus lower the toxicity on non-cancerous cells. Tar-
geting centrosomal proteins involved in microtubule
assembly, such as NEDD1, represents a novel, challenging
area of research for new anti-mitotic compounds.
Methods
Cell lines
Human cervix adenocarcinoma, HeLa (ATCC CCL-2),
human prostate carcinoma DU145 (ATCC HTB-81),
human colon adenocarcinoma DLD-1 (ATCC CCL-221),
ovarian adenocarcinoma SKOV-3, human breast adeno-
carcinoma MDA-MB-231 (HTB-26), human pancreas ade-
nocarcinoma BxPc-3 (ATCC CRL-1687), human lung
carcinoma A549 (ATCC CCL-185) and normal human
lung fibroblast MRC-5 (ATCC CCL-171) cell lines were
purchased from American Type Culture Collection (Man-
assas, VA). HeLa and MRC-5 cells were maintained in Dul-
becco's Modified Eagle's Medium supplemented with 2
mM L-GlutaMAX I and 10% fetal bovine serum (FBS).
DLD-1 and DU145 were grown in Minimum EssentialMolecular Cancer 2009, 8:10 http://www.molecular-cancer.com/content/8/1/10
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Medium supplemented with 2 mM L-Glutamine and 10%
FBS. SKOV-3 and BxPc-3 were cultured in RPMI 1640
medium without phenol red, supplemented with 2 mM L-
Glutamine and 10% FBS. A549 and MDA-MB-231 were
maintained in RPMI 1640 medium supplemented with 2
mM L-Glutamine and 10% FBS. The human colon cancer
cell lines HCT116 p53 +/+ and HCT116 p53 -/- [16],
kindly provided by Dr. Bert Vogelstein (Johns Hopkins
University School of Medicine, Baltimore, MD, USA),
were grown in McCoy's 5A medium with 10% FBS. Pri-
mary normal foreskin fibroblasts were from Dr. A. Popov
and Dr. A. Juhem (INSERM U 836, Grenoble Institute of
Neurosciences) and were grown in Dulbecco's Modified
Eagle's Medium supplemented with 2 mM L-GlutaMAX I
and 10% FBS.
RNA silencing
Double-stranded siRNA oligomers, targeting nucleotides
229–247 of human NEDD1 (GGGCAAAAGCAGACAU-
GUG) were used [14]. Control (non-silencing) siRNA was
provided by QIAGEN. Cells were plated to obtain a con-
fluency of 70 to 90% at 48 to 72 hours after transfection.
Transfections were carried out using Lipofectamine
RNAiMax (Invitrogen), according to the manufacturer's
protocol. High concentrations of siRNA were used in Fig-
ure 1, Figure 2, Figure 3, and 4: 50 nM, and in figure. 2D:
25 nM. Low concentrations were used in Figure 5 and Fig-
ure 6: 0.5 nM, or concentrations varying from 0–2.5 nM.
Flow cytometry
Cells treated with siRNAs for 48 or 72 h were harvested
with trypsin-EDTA, washed twice with PBS and stained
with propidium iodide using a Coulter DNA Prep Rea-
gents kit (Beckman-Coulter), according to the manufac-
turer's instructions. Analysis of the DNA content was done
using a LSRII flow cytometer (Becton-Dickinson). For
each experiment, 20,000 cells were analyzed using a 'dou-
blet discrimination model' to exclude aggregates of multi-
ple cells from the analysis, and data were processed using
Diva software (Becton-Dickinson). The percentages of
cells at G2/M phase of the cycle were calculated using
ModFit LT Software (Becton-Dickinson). Cell cycle analy-
sis on the basis of cyclin B1 immunofluorescence was per-
formed in 10,000 cells/experiment, at 72 hours after
siRNA transfection. Cells were rinsed in ice-cold PBS after
trypsinization, and fixed in 75% ice-cold ethanol over-
night at -20°C. Samples were then rinsed once with PBS
containing 1% FBS, and lysed for 5 min at 4°C with
0.25% Triton X-100 in the same buffer. After two further
rinses, cells were incubated for one hour at room temper-
ature with 10 μl of fluorescein-conjugated mouse anti-
human cyclin B1 antibody (GNS-1, BD Pharmingen), or
with fluorescein-conjugated mouse IgG1 monoclonal iso-
type control antibody (MOPC-21, BD Pharmingen). After
rinsing twice with PBS containing 1% FBS, cells were incu-
bated for 45 minutes at 4°C in 1 ml PBS containing 10 μg/
ml propidium iodide (Fluka).
The rate of DNA synthesis was examined by a BrdU incor-
poration method using a FITC BrdU Flow Kit (BD
Pharmingen) according to the manufacturer's instruc-
tions. Briefly, 48 h after siRNA transfection cells were
incubated for 1 hour at 37°C with 32.5 μM BrdU. Cells
were then harvested, permeabilized, and stained with a
FITC-labeled antibody against BrdU followed by the addi-
tion of 7-amino-actinomycin D (7-AAD). Cell cycle anal-
ysis was performed as described above using LSRII flow
cytometer and Diva Software (Becton-Dickinson). Cul-
tured cells without BrdU were used as nonspecific binding
controls for the FITC-labeled anti-BrdU mAb.
Western blot analysis
Cells were harvested with trypsin-EDTA, washed twice
with PBS then lysed with ice-cold lysis buffer (50 mM Tris,
pH 7.5, 150 mM NaCl, 1% Triton-X100, 2 mM EDTA)
supplemented with protease inhibitor cocktail (Com-
plete, EDTA-free, Roche) and 1 mM DTT. After sonication,
50 μg of total protein were separated on SDS-PAGE and
electrotransferred onto nitrocellulose membranes. Mem-
branes were incubated for 2 h with antibodies against
NEDD1 at 1:5,000 dilution [14], phospho-histone-H3 at
1:500 dilution (rabbit polyclonal anti-phospho-Histone
H3 Ser10 antibody, Upstate), or actin at 1:10,000 dilution
(mouse monoclonal anti-actin MAB1501), in blocking
buffer (Li-cor Biosciences) containing 0.1% Tween-20. As
secondary antibodies, IRDye 800CW-conjugated goat
anti-rabbit IgG (Li-cor) and IRDye 680CW-conjugated
goat anti-mouse IgG were used for 1 h at 1:10,000 dilu-
tion in blocking buffer (Li-cor), containing 0.1% Tween-
20 and 0.01% SDS. The protein levels of NEDD1, phos-
pho-histone-H3 and actin were determined with the
Odyssey imaging system (Li-cor Biosciences).
Immunofluorescence analysis
72 h after siRNA transfection, cells grown on coverslips
were fixed in methanol at -20°C for 15 minutes. After
rinsing three times with PBS, cells were incubated with
mouse monoclonal anti-alpha tubulin antibody (Sigma-
Aldrich, 1:1,000) in PBS + 0.1% Tween-20 + 1% BSA, for
1 h at room temperature. Following three rinses with PBS,
Alexa 488 goat anti-mouse antibody (Molecular Probes,
1:1,000 in PBS + 0.1% Tween-20 + 1% BSA) was added for
45 minutes. DNA was labeled with DAPI (1 μg/ml). Cells
were examined with a fluorescence microscope (Axiovert,
Carl Zeiss MicroImaging) using a 63x/1.4NA Plan-
Apochromat lens. Images were acquired with an AxioCam
MRm camera and AxioVision software (Carl Zeiss Micro-
Imaging). Mitotic indices were determined using morpho-
logical criteria, by counting cells that display DNA
condensation and mitotic spindles.Molecular Cancer 2009, 8:10 http://www.molecular-cancer.com/content/8/1/10
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Drug treatment and combination analysis
2 × 105 cells were plated in 6-well plates (35 mm in diam-
eter) and allowed to adhere for 24 hours; the transfection
of double-stranded siRNA oligonucleotides was done as
described above, at variable concentrations (0–2.5 nM).
For combination studies, cells were transfected first and
BI2536 (kindly provided by the 'Centre de Recherche en
Oncologie Pierre Fabre'), paclitaxel or monastrol (Sigma)
were added 4 hours after transfection in fresh medium.
Cells were harvested 48 hours after the beginning of trans-
fection, and viable cells were counted by trypan blue
exclusion analysis using a Vi-CELL Viability Analyzer
(Beckman Coulter).
In Figure 5A, Figure 5D, Figure 5E, the combination indi-
ces (CI) were calculated using the following equation
[21]:
CI = CN,x/ICx,N + CD,x/ICx,D, where CN,x and CD,x are the
concentrations of NEDD1-siRNA and drugs (BI2536,
paclitaxel or monastrol) used in combination to achieve
x% drug effect, and ICx,N and ICx,D are the concentrations
for single agents to achieve the same effect. A CI of less
than 1 indicates synergy, equal to 1 indicates additivity,
and more than 1 indicates antagonism [21]. In Figure 5B,
Figure 5C, Figure 5F, Figure 5G, the theoretical dose-
response curves for additivity were calculated using the
formula [22]:
TA = EN - (ED × EN/100) (Figure 5B) or TA = ED - (ED × EN/
100) (Figure 5C, Figure 5F, Figure 5G), where EN is the
effect of NEDD1-siRNA alone, and ED is the effect of the
drug alone in %.
Abbreviations
BrdU: 5-bromo-2-deoxyuridine; DAPI: 4',6-diamidino-2-
phenylindole; Eg5: egg protein 5; GCP: gamma-tubulin
complex protein; NEDD1: neural precursor cell expressed,
developmentally down-regulated gene 1; Plk1: polo-like
kinase 1; CI: combination index; SD: standard deviation.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
V.T. and L.H. contributed equally, by performing cell cul-
ture experiments, transfection, immunofluorescence,
western blotting, data analysis, and participating in draft-
ing the manuscript. N.R. carried out flow cytometry and
data analysis. C.E. participated in the design and analysis
of the pharmacological experiments, and in drafting the
manuscript. A.M. participated in the conception of the
project, coordinated the study, and participated in draft-
ing the manuscript. All authors read and approved the
final manuscript.
Acknowledgements
We thank our colleagues at the Unité Mixte CNRS-Pierre Fabre 2587 and 
at the Centre de Recherche en Oncologie Expérimentale for advice and for 
the donation of reagents. In particular, we thank Viviane Brel, Vanessa 
Offrete, and Jean-Philippe Annereau for technical help and valuable discus-
sions. Drs Andrei Popov (Grenoble Institute for Neurosciences) and Bert 
Vogelstein (Johns Hopkins University) are thanked for the donation of 
fibroblasts and colon carcinoma cells. V.T. was supported by a postdoctoral 
fellowship from 'Fonds Structurels de l'Europe'. The research groups of 
A.M. and C.E. are supported by the Centre National de la Recherche Sci-
entifique and by the Pierre Fabre Group.
References
1. Fukasawa K: Centrosome amplification, chromosome instabil-
ity and cancer development.  Cancer Lett 2005, 230:6-19.
2. Fukasawa K: Oncogenes and tumour suppressors take on cen-
trosomes.  Nat Rev Cancer 2007, 7:911-924.
3. Nigg EA: Origins and consequences of centrosome aberra-
tions in human cancers.  Int J Cancer 2006, 119:2717-2723.
4. Hinchcliffe EH, Miller FJ, Cham M, Khodjakov A, Sluder G: Require-
ment of a centrosomal activity for cell cycle progression
through G1 into S phase.  Science 2001, 291:1547-1550.
5. Khodjakov A, Rieder CL: Centrosomes enhance the fidelity of
cytokinesis in vertebrates and are required for cell cycle pro-
gression.  J Cell Biol 2001, 153:237-242.
6. Quintyne NJ, Schroer TA: Distinct cell cycle-dependent roles
for dynactin and dynein at centrosomes.  J Cell Biol 2002,
159:245-254.
7. Augustin A, Spenlehauer C, Dumond H, Ménissier-De Murcia J, Piel
M, Schmit AC, Apiou F, Vonesch JL, Kock M, Bornens M, De Murcia
G: PARP-3 localizes preferentially to the daughter centriole
and interferes with the G1/S cell cycle progression.  J Cell Sci
2003, 116:1551-1562.
8. Gromley A, Jurczyk A, Sillibourne J, Halilovic E, Mogensen M,
Groisman I, Blomberg M, Doxsey S: A novel human protein of the
maternal centriole is required for the final stages of cytoki-
nesis and entry into S phase.  J Cell Biol 2003, 161:535-545.
9. Keryer G, Witczak O, Delouvée A, Kemmner WA, Rouillard D,
Tasken K, Bornens M: Dissociating the centrosomal matrix
protein AKAP450 from centrioles impairs centriole duplica-
tion and cell cycle progression.  Mol Biol Cell 2003, 14:2436-2446.
10. Srsen V, Gnadt N, Dammermann A, Merdes A: Inhibition of cen-
trosome protein assembly leads to p53-dependent exit from
the cell cycle.  J Cell Biol 2006, 174:625-630.
11. Mikule K, Delaval B, Kaldis P, Jurcyzk A, Hergert P, Doxsey S: Loss
of centrosome integrity induces p38-p53-p21-dependent G1-
S arrest.  Nat Cell Biol 2007, 9:160-170.
12. Uetake Y, Loncarek J, Nordberg JJ, English CN, La Terra S, Khodjakov
A, Sluder G: Cell cycle progression and de novo centriole
assembly after centrosomal removal in untransformed
human cells.  J Cell Biol 2007, 176:173-182.
13. Whitehurst AW, Bodemann BO, Cardenas J, Ferguson D, Girard L,
Peyton M, Minna JD, Michnoff C, Hao W, Roth MG, Xie XJ, White
MA: Synthetic lethal screen identification of chemosensitizer
loci in cancer cells.  Nature 2007, 446:815-819.
14. Haren L, Remy MH, Bazin I, Callebaut I, Wright M, Merdes A:
NEDD1-dependent recruitment of the gamma-tubulin ring
complex to the centrosome is necessary for centriole dupli-
cation and spindle assembly.  J Cell Biol 2006, 172:505-515.
15. Lüders J, Patel UK, Stearns T: GCP-WD is a gamma-tubulin tar-
geting factor required for centrosomal and chromatin-medi-
ated microtubule nucleation.  Nat Cell Biol 2006, 8:137-147.
16. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP,
Sedivy JM, Kinzler KW, Vogelstein B: Requirement for p53 and
p21 to sustain G2 arrest after DNA damage.  Science 1998,
282:1497-1501.
17. Steegmaier M, Hoffmann M, Baum A, Lénárt P, Petronczki M, Krssák
M, Gürtler U, Garin-Chesa P, Lieb S, Quant J, Grauert M, Adolf GR,
Kraut N, Peters JM, Rettig WJ: BI 2536, a potent and selective
inhibitor of polo-like kinase 1, inhibits tumor growth in vivo.
Curr Biol 2007, 17:316-322.
18. Lénárt P, Petronczki M, Steegmaier M, Di Fiore B, Lipp JJ, Hoffmann
M, Rettig WJ, Kraut N, Peters JM: The small-molecule inhibitorPublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Molecular Cancer 2009, 8:10 http://www.molecular-cancer.com/content/8/1/10
Page 13 of 13
(page number not for citation purposes)
BI 2536 reveals novel insights into mitotic roles of polo-like
kinase 1.  Curr Biol 2007, 17:304-315.
19. McInnes C, Mazumdar A, Mezna M, Meades C, Midgley C, Scaerou F,
Carpenter L, Mackenzie M, Taylor P, Walkinshaw M, Fischer PM,
Glover D: Inhibitors of Polo-like kinase reveal roles in spindle-
pole maintenance.  Nat Chem Biol 2006, 2:608-617.
20. Peters U, Cherian J, Kim JH, Kwok BH, Kapoor TM: Probing cell-
division phenotype space and Polo-like kinase function using
small molecules.  Nat Chem Biol 2006, 2:618-626.
21. Chou TC, Talalay P: Quantitative analysis of dose-effect rela-
tionships: the combined effects of multiple drugs or enzyme
inhibitors.  Adv Enzyme Regul 1984, 22:27-55.
22. Etievant C, Kruczynski A, Barret JM, Perrin D, van Hille B, Guminski
Y, Hill BT: F11782, a dual inhibitor of topoisomerases I and II
with an original mechanism of action in vitro, and markedly
superior in vivo antitumor activity, relative to three other
dual topoisomerase inhibitors, intoplicin, aclarubicin and
TAS-103.  Cancer Chemother Pharmacol 2000, 46:101-113.
23. Mayer TU, Kapoor TM, Haggarty SJ, King RW, Schreiber SL,
Mitchison TJ: Small molecule inhibitor of mitotic spindle bipo-
larity identified in a phenotype-based screen.  Science 1999,
286:971-974.
24. Jackson JR, Patrick DR, Dar MM, Huang PS: Targeted anti-mitotic
therapies: can we improve on tubulin agents?  Nat Rev Cancer
2007, 7:107-117.
25. Khodjakov A, Rieder CL: The sudden recruitment of gamma-
tubulin to the centrosome at the onset of mitosis and its
dynamic exchange throughout the cell cycle, do not require
microtubules.  J Cell Biol 1999, 146:585-596.
26. Sunkel CE, Glover DM: Polo, a mitotic mutant of Drosophila
displaying abnormal spindle poles.  J Cell Sci 1988, 89:25-38.
27. Llamazares S, Moreira A, Tavares A, Girdham C, Spruce BA, Gonzalez
C, Karess RE, Glover DM, Sunkel CE: Polo encodes a protein
kinase homolog required for mitosis in Drosophila.  Genes Dev
1991, 5:2153-2165.
28. Lane HA, Nigg EA: Antibody microinjection reveals an essen-
tial role for human polo-like kinase 1 (Plk1) in the functional
maturation of mitotic centrosomes.  J Cell Biol 1996,
135:1701-1713.
29. Qian YW, Erikson E, Li C, Maller JL: Activated polo-like kinase
Plx1 is required at multiple points during mitosis in Xenopus
laevis.  Mol Cell Biol 1998, 18:4262-4271.
30. van Vugt MA, Weerdt BC van de, Vader G, Janssen H, Calafat J,
Klompmaker R, Wolthuis RM, Medema RH: Polo-like kinase-1 is
required for bipolar spindle formation but is dispensable for
anaphase promoting complex/Cdc20 activation and initia-
tion of cytokinesis.  J Biol Chem 2004, 279:36841-36854.
31. Sumara I, Gimenez-Abian JF, Gerlich D, Hirota T, Kraft C, de la Torre
C, Ellenberg J, Peters JM: Roles of polo-like kinase 1 in the
assembly of functional mitotic spindles.  Curr Biol 2004,
14:1712-1722.
32. Shi J, Orth JD, Mitchison T: Cell type variation in responses to
antimitotic drugs that target microtubules and kinesin-5.
Cancer Res 2008, 68:3269-3276.